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ABSTRACT:  
The lower detection limit for two distinct crystalline phases by 1H magic-angle 
spinning (MAS) solid-state NMR is investigated for a minority amount of cimetidine 
(anhydrous polymorph A) in a physical mixture with the anhydrous hydrochloride salt 
of cimetidine. Specifically, two-dimensional 1H double-quantum (DQ) MAS spectra 
of polymorph A and the anhydrous hydrochloride salt constitute fingerprints for the 
presence of each of these solid forms. For solid-state NMR data recorded at a 1H 
Larmor frequency of 850 MHz and a MAS frequency of 30 kHz on ~10 mg of 
sample, it is shown that, by following the pair of cross peaks at a 1H DQ frequency of 
7.4 + 11.6 = 19.0 ppm that are unique to polymorph A, the level of detection for 
polymorph A in a physical mixture with the anhydrous hydrochloride salt is a 
concentration of 1% w/w. 
Keywords: solid state; NMR; physical characterisation; analytical chemistry; 
hydrogen bonding; magic-angle spinning, double-quantum  
INTRODUCTION 
Salt formation is the most general and effective method for improving the 
aqueous solubility and dissolution rate of acidic and basic drugs. Currently nearly half 
of all active pharmaceutical ingredients (APIs) used in medication are in salt forms.1 
However, during various processing steps such as milling, compression, drying and 
granulation, a salt can become unstable chemically and physically, i.e., it may 
transform to its free acid/base form or into other polymorphs or solvates. Many of the 
commonly used excipients in tablet formulations are acidic or basic and can, thus, 
change the local pH of a system. This can affect the stability of the salt and cause the 
transformation of the salt to the corresponding free acid/base form. The solid-state 
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transformation from a salt to a free form will alter key properties of the API, such as 
solubility and dissolution behaviour, leading to undesired changes in the 
bioavailability of the API.2 In order to monitor the quality of pharmaceuticals, an 
effective and highly sensitive quantitation method is required. 
A variety of techniques have been used to characterize the physicochemical 
properties of pharmaceuticals,3 including powder X-ray diffraction (PXRD), 
differential scanning calorimetry (DSC) and vibrational spectroscopies, notably infra-
red (IR) and Raman.  Although PXRD is considered the definitive test for the 
identification of a specific solid-state form, the effectiveness of PXRD for quantitative 
analysis of mixtures of solid phases can be diminished when the effects of preferred 
orientation are significant;4 however, if the crystal structures of all the solid forms 
present in the mixture are known, then quantitative analysis can be carried out by 
Rietveld refinement in which the effects of preferred orientation are taken rigorously 
into consideration. For example, Li et al. have shown5 that the error associated with 
distinguishing polymorphs I and II of sulfamerazine by DSC or PXRD was ±3%, 
which is superior to that achieved by Raman spectroscopy. Siddiqui et al. have also 
used PXRD (and solid-state NMR) to quantify the amount of crystalline tacrolimus 
solid dispersions,6,7 while Macfhionnghaile et al. have investigated the effect of ball-
milling and cryomilling on sulfamerazine using PXRD, IR and near IR spectroscopy.8 
Using terahertz (THz) spectroscopy,9 Strachan et al. have shown that the 
concentration of carbamazepine form III in a physical mixture with form I can be 
detected down to a concentration of 1.5%.10 Moreover, Hisazumi et al. have used THz 
spectroscopy to distinguish between anhydrous and hydrate forms of theophylline 
with an error of 3% in a pharmaceutical formulation.11 Recently, Thakral et al. have 
used PXRD to follow salt disproportionation,12 in which the PXRD data were 
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measured using a two-dimensional area detector – using this technique, conventional 
one-dimensional PXRD patterns that are free from the effects of preferred orientation 
can be obtained by appropriate integration of the two-dimensional data. 
Solid-state nuclear magnetic resonance (NMR) spectroscopy is an important 
method for pharmaceutical analysis.13-17 While the workhorse method is 13C cross-
polarization (CP) magic-angle spinning (MAS), the potential of applying 1H fast MAS 
NMR is increasingly recognized for solid-state analysis.18-48 In particular, the 1H 
double-quantum (DQ) solid-state NMR experiment is a powerful probe of dipolar-
coupled protons, with DQ peaks observed for close (typically less than 3.5 Å) 
through-space H···H proximities.49-51 Thus, a two-dimensional 1H DQ spectrum 
represents a “fingerprint” for a specific three-dimensional packing arrangement 
adopted by an organic molecule, emphasising the advantage over one-dimensional 1H 
or 13C spectra of spreading out into two dimensions. In this way, by using a high-
resolution 1H DQ CRAMPS (combined rotation and multiple-pulse spectroscopy) 
approach,52 it has been shown how the presence of only the anhydrous form and not a 
hydrate form of an API in tablet formulation can be established.19 Due to the spectral 
noise associated with the application of 1H homonuclear decoupling in the CRAMPS 
approach, it is only possible to conclude that the hydrate form is absent within a 
detection limit of ~5% for the spectra presented in Ref.19. An alternative approach is 
to use a combination of fast MAS and high magnetic field to give 1H DQ MAS 
spectra, where the resolution, while not as good as with the 1H DQ CRAMPS 
method,51 is sufficient to resolve distinct spectral features. For the specific case of the 
anhydrous hydrochloride salt of cimetidine (the crystal structure of which has been 
determined recently53 by a combined PXRD and NMR crystallography strategy) and 
the free form of cimetidine (anhydrous polymorph A), this paper investigates the 
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lower limit of detection of a minority solid-state form of an API, present in a physical 
mixture with another crystalline phase of the same API, using 1H DQ MAS NMR 
spectroscopy.  
EXPERIMENTAL SECTION 
Cimetidine and cimetidine hydrochloride were purchased from Sigma-Aldrich 
and used without further purification. The identification of the specific solid-state 
form was confirmed by powder X-ray diffraction as shown in Refs.33,53. Samples 
containing 10%, 5%, 1% and 0.5% w/w polymorph A / anhydrous HCl salt were 
prepared by physically mixing appropriately weighed quantities of the two pure solid 
phases. 
Solid-state NMR experiments were performed on a Bruker Avance III 
spectrometer operating at a 1H Larmor frequency of 850.2 MHz (B0 = 20.0 T) using a 
Bruker triple-resonance probe, operating in double-resonance mode, supporting rotors 
of 2.5 mm outer diameter (corresponding to ~10 mg of sample). A MAS frequency of 
30 kHz was used. The pulse sequence and coherence transfer pathway diagram for the 
1H DQ MAS49 experiment using BABA (back-to-back) recoupling54,55 experiment are 
shown in Figure 7 of Ref.56. A 16-step phase cycle was used to select ∆p = ±2 on the 
DQ excitation block and ∆p = −1 on the final 90° pulse, where p is the coherence 
order. The 1H 90° pulse length was 2.5 µs. In all experiments, 160 t1 FIDs were 
recorded with a rotor-synchronized t1 increment of 33.3 µs using the States-TPPI 
(time-proportional phase incrementation) method to achieve sign discrimination in F1. 
For the anhydrous HCl salt of cimetidine and polymorph A of cimetidine, 16 
transients were co-added with a recycle delay of 3 s. For the physical mixtures of 
polymorph A and the anhydrous HCl salt, a recycle delay of 9 s was used and 16 
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(10% and 5% w/w mixture samples), 48 (1% w/w mixture sample) and 112 transients 
(0.5% w/w mixture sample) were co-added. The experimental times were thus 2 hours 
(anhydrous cimetidine hydrochloride and cimetidine polymorph A), 6 hours (10% and 
5% w/w mixture samples), 19 hours (1% w/w mixture sample) and 44 hours (0.5% 
w/w mixture sample).  
1H chemical shifts are referenced with respect to neat TMS using adamantane 
as a secondary reference (1.85 ppm for 1H).57 Experimental 1H chemical shifts are 
stated to an accuracy of ±0.1 ppm. 
RESULTS AND DISCUSSION 
1H DQ MAS Solid-State NMR Spectra 
In previous studies, 13C CP MAS one-dimensional spectra, as well as the 
results of various heteronuclear dipolar experiments, have been presented for a free 
form of cimetidine (polymorph A),58,59 while a 13C CP MAS spectrum of the 
anhydrous HCl salt of cimetidine as well as a GIPAW (gauge-including projector-
augmented wave) calculation60,61 of the NMR parameters (for the reported crystal 
structure53 following geometry optimization) have been presented recently. Tatton et 
al. have also presented 15N-1H spectral-editing and 14N-1H and 15N-1H correlation 
spectra for polymorph A of cimetidine, together with GIPAW calculations of the 
chemical shielding and electric field gradient tensors for the reported crystal 
structure62 following geometry optimization.33 Note that distances stated in this paper 
are from the geometry-optimized crystal structures on which these GIPAW 
calculations were carried out (available as Supporting Information with Refs. 33,53). 
Fig. 1a and 1b present 1H DQ MAS NMR spectra of (a) the anhydrous HCl 
salt of cimetidine and (b) polymorph A of cimetidine, recorded at a 1H Larmor 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
7 
 
frequency of 850 MHz and a MAS frequency of 30 kHz. Since 1H linewidths for the 
strongly dipolar-coupled network of protons in organic solids decrease with 
increasing MAS frequency,63,64 narrower 1H linewidths would be observed using the 
higher MAS frequencies of >60 kHz that can be achieved with rotors of smaller outer 
diameter (1.3 mm and less). However, the improved resolution would come at the cost 
of lower sensitivity associated with the considerably reduced sample volume 
(corresponding to sample mass ~1 mg or less). Enhanced resolution could also be 
achieved using the 1H DQ CRAMPS approach (e.g., see Fig. 3 of Ref.51) but, as noted 
in the Introduction, the disadvantage of using 1H homonuclear decoupling is the 
observation of additional "noise" in the spectra which limits the lower detection of the 
minority phase to ~5%. For these reasons, it was decided that 30 kHz MAS at a 1H 
Larmor frequency of 850 MHz provided the best compromise of sufficiently high-
resolution and optimum sensitivity for 1H DQ MAS NMR spectroscopy of the 
anhydrous HCl salt and polymorph A of cimetidine – see the spectra presented in Fig. 
1a and 1b. 
 
The 1H DQ MAS NMR spectra presented in Fig. 1 were recorded using one 
rotor period of BABA recoupling.54,55 Such 1H DQ MAS NMR spectra probe DQ 
coherences between pairs of through-space dipolar coupled protons corresponding to 
a close (typically less than 3.5 Å) H···H distance,49,51 with DQ peaks observed at the 
sum of the two single-quantum (SQ) frequencies. Table 1 presents an assignment of 
the experimentally observed 1H chemical shifts for polymorph A and the anhydrous 
HCl salt of cimetidine based on GIPAW calculations (as reported previously33,53). The 
significant change in the 1H chemical shift of H3 reflects the change from an NH·· ·N 
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intermolecular hydrogen bond with N12 as the acceptor in polymorph A (involving 
uncharged donor and acceptor groups) to an NH+· · ·Cl− intermolecular hydrogen bond 
(involving charged donor and acceptor groups) in the anhydrous HCl salt. 
Tables 2 and 3 list H···H proximities under 3.5 Å for the NH and imidazole 
CH protons and the corresponding 1H DQ shifts for the anhydrous HCl salt and 
polymorph A of cimetidine, respectively. For the anhydrous HCl salt, the NH+ (H1) 
and NH (H3) imidazole 1H chemical shifts overlap (at 15.0 ppm, see Table 1). Thus, 
in the 1H DQ MAS spectrum in Fig. 1a, the pair of 1H DQ peaks at δDQ = 15.0 + 9.4 = 
24.4 ppm corresponds to an intramolecular proximity of 2.57 Å for the imidazole CH 
(H2) with both the NH+ (H1) and NH (H3) protons – see Table 2. We also note the 
very weak diagonal peak at δDQ = 15.0 + 15.0 = 30.0 ppm in Fig. 1a that corresponds 
to a 3.43 Å intermolecular proximity of the NH+ (H1) and NH (H3) protons (also see 
Table 2). As described in Ref. 65, to a first approximation, the relative intensity of 
distinct 1H DQ peaks at the same 1H single-quantum chemical shift is proportional to 
the ratio of the square of the dipolar coupling constants and hence is inversely 
proportional to ratio of H···H distances to the sixth power – note that (3.43/2.57)6 = 
5.7. Other cross peaks observed for the NH groups in the 1H DQ MAS spectra in Fig. 
1a and 1b are due to intra- and intermolecular proximities to CH2 and CH3 protons 
(see Tables 2 and 3). 
This study is focused on the pair of 1H DQ peaks due to the intramolecular 
proximity of 2.57 and 2.55 Å for the imidazole H2 (CH) and H3 (NH) protons, 
whereby δDQ = 15.0 + 9.4 = 24.4 ppm in Fig. 1a for the anhydrous HCl salt and δDQ = 
11.6 + 7.4 = 19.0 ppm in Fig. 1b for polymorph A. The evident change in the 
positions of the pair of 1H DQ peaks due to the intramolecular proximity of the 
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imidazole H2 (CH) and H3 (NH) protons between the anhydrous HCl salt and 
polymorph A constitutes a "fingerprint" that is a diagnostic for the presence of either 
or both of the distinct solid-state forms. 
Probing the Level of Detection of a Minority Phase in a Physical Mixture of Two 
Distinct Crystalline Phases 
To determine the level of detection by 1H DQ MAS NMR of polymorph A of 
cimetidine in a physical mixture with the anhydrous HCl salt of cimetidine, spectra 
were recorded for samples comprising 10%, 5%, 1% and 0.5% w/w mixtures of 
polymorph A / anhydrous HCl salt. Specifically, Fig. 1c presents a 1H DQ MAS NMR 
spectrum of the 10% w/w mixture (note the lower base contour in Fig. 1c as compared 
to Fig. 1a and 1b). It is evident that a weak pair of 1H DQ peaks at δDQ = 11.6 + 7.4 = 
19.0 ppm due to polymorph A is observed in addition to the stronger 1H DQ peaks at 
δDQ = 15.0 + 9.4 = 24.4 ppm due to the anhydrous HCl salt. Thus, it is necessary to 
focus on the peaks observed at a 1H DQ frequency of 19.0 ppm, and Fig. 2 presents 
slices at this DQ frequency for (a) the anhydrous HCl salt of cimetidine, (b) 
polymorph A of cimetidine, and (c-f) physical mixtures of polymorph A with the 
anhydrous HCl salt with (c) 10%, (d) 5%, (e) 1%, and (f) 0.5% w/w of polymorph A. 
For the anhydrous HCl salt, we note that there are 1H DQ peaks at δDQ = 15.0 + 4.0 = 
19.0 ppm due to proximity with aliphatic protons − see Figs. 1a and 2a. The spreading 
into two dimensions allows these to be distinguished from the 1H DQ peaks at δDQ = 
11.6 + 7.4 = 19.0 ppm, characteristic of polymorph A. Following the dashed lines 
through the peaks at δSQ = 11.6 and 7.4 ppm, it is evident that the 1H DQ peaks due to 
polymorph A are still evident above the noise level down to the 1% w/w mixture in 
Fig. 2e. This conclusion is confirmed by the signal to noise analysis presented in 
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Table 4 for the peaks at a 1H DQ frequency of 19.0 ppm for the H2 and H3 1H SQ 
resonances at 11.6 and 7.4 ppm. Following the guidance of the International 
Conference on Harmonisation of Technical Requirements for Registration of 
Pharmaceuticals for Human Use, Validation of Analytical Procedures: Text and 
Methodology Q2(R1), section 6.2 states that “A signal-to-noise ratio between 3 or 2:1 
is generally considered acceptable for estimating the detection limit”.66 As such, the 
data in Table 4 establishes 1% w/w as the level of detection using 1H DQ MAS NMR 
at 30 kHz MAS and a 1H Larmor frequency of 850 MHz for two crystalline phases of 
cimetidine. 
 
CONCLUSIONS 
Two distinct crystalline phases of cimetidine, polymorph A and the anhydrous 
HCl salt, are clearly distinguished using 1H DQ MAS solid-state NMR spectroscopy 
by focusing on the pair of 1H DQ peaks due to the intramolecular proximity (2.55 or 
2.57 Å) of the neighbouring H2 (CH) and H3 (NH) protons of the imidazole ring. 
Protonation at the N1 site in the anhydrous HCl salt as well as the fact that the two 
distinct solid-state forms have different intermolecular hydrogen-bonding 
arrangements leads to 1H DQ peaks at δDQ = 15.0 + 9.4 = 24.4 ppm for the anhydrous 
HCl salt and at δDQ = 11.6 + 7.4 = 19.0 ppm for polymorph A. By spreading out the 
peaks into two dimensions, the observation of 1H DQ peaks at δDQ = 11.6 + 7.4 = 19.0 
ppm is an unambiguous indicator of the presence of polymorph A. Using this 
"fingerprint", solid-state NMR experiments carried out at a 1H Larmor frequency of 
850 MHz and a MAS frequency of 30 kHz have shown that polymorph A can be 
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detected and quantified in a physical mixture with the anhydrous HCl salt down to a 
concentration of 1% w/w. Considering literature reports (see Introduction), this level 
of detection matches and in some cases improves upon that reported for other 
analytical techniques, e.g., PXRD, DSC, Raman spectroscopy and THz spectroscopy. 
In particular, we emphasize that distinguishing between two crystalline phases 
represents a different challenge to the identification of a minority amount of a 
crystalline phase in the presence of an amorphous phase. 
We note that employing 1H DQ MAS represents a complementary approach to 
solid-state NMR of other nuclei, notably 13C and 19F.67,68 Moreover, it has recently 
been shown that the sensitivity of solid-state NMR spectroscopy of moderately sized 
organic molecules can be significantly enhanced (e.g., by 5 times for paracetamol) by 
employing dynamic nuclear polarization (DNP), such that 13C refocused 
INADEQUATE spectra can be recorded at natural isotopic abundance in 16 hours for 
sulfathiazole (which has a long T1 relaxation time, necessitating a recycle delay of 30 
s)69 and 15N-1H correlation spectra can be obtained also at natural isotopic abundance 
for a pharmaceutical formulation.70 With the recent development of new DNP 1.3 mm 
MAS probe technology that allows faster MAS,71 this approach seems promising for 
progressing to even lower levels of detection of minority solid-state forms by 1H DQ 
MAS. This approach would also reduce the required experimental time (in this work, 
19 hours for the two-dimensional spectrum of the 1% w/w sample), noting that 
experimental times are typically shorter for other techniques such as PXRD, Raman 
and IR. Finally, as shown in our earlier work employing a 1H DQ CRAMPS 
approach,19 we note that the 1H DQ solid-state NMR method presented here is readily 
applicable to tablet formulations with the shift of 1H DQ peaks due to hydrogen-
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bonded protons to high ppm helping to avoid overlap with 1H resonances of the 
excipients. 
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Figure Captions 
 
Figure 1. 1H (850 MHz) DQ MAS (30 kHz) spectra of (a) the anhydrous HCl salt of 
cimetidine, (b) polymorph A of cimetidine, and (c) a 10% w/w physical mixture of 
polymorph A with the anhydrous HCl salt. An assignment of the 1H chemical shifts is 
presented in Table 1, while Tables 2 and 3 list the expected 1H DQ peaks based on H-
H proximities extracted from the geometry-optimized (CASTEP) crystal structures. 
The thick horizontal lines in (a) and (b) denote the pair of 1H DQ peaks corresponding 
to the intramolecular proximity of the imidazole H2 (CH) and H3 (NH) protons, 
noting that for the anhydrous HCl salt this overlaps with the pair of 1H DQ peaks 
corresponding to the intramolecular proximity of the imidazole H2 (CH) and H1 
(NH+) protons. The base contour levels are at (a) 5.4%, (b) 11% and (c) 2.6% with 
respect to the maximum peak height. (Note that a conference abstract has presented 
the spectra in this figure in a different format.72) 
 
Figure 2. Slices corresponding to a 1H DQ frequency of 19.0 ppm, as extracted from 
two-dimensional 1H (850 MHz) DQ MAS (30 kHz) spectra of (a) the anhydrous HCl 
salt of cimetidine, (b) polymorph A of cimetidine, and (c-f) physical mixtures of 
polymorph A with the anhydrous HCl salt with (c) 10%, (d) 5%, (e) 1%, and (f) 0.5% 
w/w of polymorph A.  
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Tables 
Table 1. Experimentala and GIPAW calculatedb 1H chemical shifts (in ppm) for the 
anhydrous HCl salt and polymorph A of cimetidine 
atom label atom descriptor 
anhydrous HCl salt polymorph A 
expt. calc. expt. calc. 
H1 NH+ 15.0 15.5 − − 
H2 CH 9.4 9.2 7.4 7.1 
H3 NH 15.0 15.3 11.6 11.9 
H6a CH2 3.6 4.3 4.0 3.4 
H6b CH2 3.6 3.8 4.0 3.0 
H7a-cc CH3 2.6 2.9 2.0 1.3 
H8a CH2 2.6 2.4 3.0 1.3 
H8b CH2 2.6 0.7 3.0 0.2 
H9a CH2 2.6 2.8 3.0 2.4 
H9b CH2 2.6 1.9 3.0 2.7 
H10 NH 5.0 4.6 8.2 8.2 
H15 NH 6.7 6.9 9.7 9.6 
H16a-cc CH3 2.6 1.4 2.0 1.5 
a
 It is not possible to distinguish separate CH2 and CH3 1H resonances in the 
experimental spectra. 
b
 Calculated isotropic chemical shifts are obtained from the calculated absolute 
shielding as δisocalc  =  σref – σcal, where σref  =  30.0 ppm.  
c
 For CH3 groups, the stated value of the calculated isotropic chemical shift is the 
average for the three protons.  
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Table 2. H···H proximitiesa (< 3.5 Å) and corresponding 1H DQ shifts (see Fig. 1a) 
for the NH and imidazole CH protons in the anhydrous HCl salt of cimetidine. 
 Atom label δSQ / ppm δDQ / ppm distance / Å 
H1 (NH+) H2 (CH) 9.4 24.4 2.57 
(15.0 ppm) H6b (CH2) 3.6 18.6 2.70 
 H7c (CH3) 2.6 17.6 2.82 
 H16c (CH3) 2.6 17.6 2.94 
 H16a (CH3) 2.6 17.6 3.18 
 H3 (NH) 15.0 30.0 3.43 
 H7a (CH3) 2.6 17.6 3.49 
H2 (CH) H1 (NH+) 15.0 24.4 2.57 
(9.4 ppm) H3 (CH) 15.0 24.4 2.57 
 H7c (CH3) 2.6 12.0 2.69 
 H6b (CH2) 3.6 13.0 2.82 
 H6a (CH2) 3.6 13.0 3.06 
 H6a (CH2) 3.6 13.0 3.13 
 H16b (CH3) 2.6 12.0 3.39 
H3 (NH) H2 (CH) 9.4 24.4 2.57 
(15.0 ppm) H6b (CH2) 3.6 18.6 2.71 
 H7c (CH3) 2.6 17.6 2.73 
 H6a (CH2) 3.6 18.6 2.95 
 H7b (CH3) 2.6 17.6 3.04 
 H9a (CH2) 2.6 17.6 3.15 
 H16c (CH3) 2.6 17.6 3.35 
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 H6a (CH2) 3.6 18.6 3.39 
 H1 (NH+) 15.0 30.0 3.43 
H10 (NH) H9a (CH2) 2.6 7.6 2.29 
(5.0 ppm) H9b (CH2) 2.6 7.6 2.94 
 H8b (CH2) 2.6 7.6 2.98 
 H7b (CH3) 2.6 7.6 3.03 
 H16c (CH3) 2.6 7.6 3.31 
 H8a (CH2) 2.6 7.6 3.33 
 H7a (CH3) 2.6 7.6 3.36 
H15 (NH) H9b (CH2) 2.6 9.3 2.17 
(6.7 ppm) H16a (CH3) 2.6 9.3 2.24 
 H8a (CH2) 2.6 9.3 2.26 
 H16b (CH3) 2.6 9.3 2.72 
 H16c (CH3) 2.6 9.3 2.93 
 H8a (CH2) 2.6 9.3 2.94 
a
 Distances are stated for the geometry-optimized (CASTEP) crystal structure. 
Intermolecular proximities are in italics. 
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Table 3. H···H proximitiesa (< 3.5 Å) and corresponding 1H DQ shifts (see Fig. 1b) 
for the NH and imidazole CH protons in the geometry-optimized (CASTEP) crystal 
structure of polymorph A of cimetidine. 
 Atom label δSQ / ppm δDQ / ppm distance / Å 
H2 (CH) H3 (NH) 11.6 19.0 2.55 
(7.4 ppm) H16a (CH3) 2.0 9.4 2.59 
 H7c (CH3) 2.0 9.4 2.87 
 H7a (CH3) 2.0 9.4 2.93 
 H15 (NH) 9.7 17.1 3.00 
 H7b (CH3) 2.0 9.4 3.05 
 H6b (CH2) 4.0 11.4 3.27 
 H16c (CH3) 2.0 9.4 3.50 
H3 (NH) H16b (CH3) 2.0 13.6 2.52 
(11.6 ppm) H2 (CH) 7.4 19.0 2.55 
 H7a (CH3) 2.0 13.6 2.59 
 H7b (CH3) 2.0 13.6 2.81 
 H7c (CH3) 2.0 13.6 3.09 
 H7b (CH3) 2.0 13.6 3.10 
 H16a (CH3) 2.0 13.6 3.13 
H10 (NH) H9a (CH2) 3.0 11.2 2.27 
(8.2 ppm) H16c (CH3) 2.0 10.2 2.71 
 H9b (CH2) 3.0 11.2 2.93 
 H8b (CH2) 3.0 11.2 2.99 
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 H8a (CH2) 3.0 11.2 3.42 
H15 (NH) H9b (CH2) 3.0 12.7 2.20 
(9.7 ppm) H16a (CH3) 2.0 11.7 2.22 
 H8a (CH2) 3.0 12.7 2.29 
 H16c (CH3) 2.0 11.7 2.81 
 H16b (CH3) 2.0 11.7 2.90 
 H2 (CH) 7.4 16.1 3.00 
 H6a (CH2) 4.0 13.7 3.19 
 H7b (CH3) 2.0 11.7 3.22 
 H7c (CH3) 2.0 11.7 3.40 
a
 Distances are stated for the geometry-optimized (CASTEP) crystal structure. 
Intermolecular proximities are in italics. 
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Table 4. Signal to noise ratios for the peaks at a 1H DQ frequency of 19.0 ppm for the 
1H SQ H2 and H3 resonances at 11.6 and 7.4 ppm (see Figure 2) for physical mixtures 
of polymorph A with the anhydrous HCl salt. 
w/w of polymorph A H2 H3 
10% 16.6 16.2 
5% 6.3 7.0 
1% 3.3 2.4 
0.5% 1.6 1.0 
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